Pharmacologic Considerations for Youth with Posttraumatic Stress Disorder.
10.5765/jkacap.2017.28.1.14
- Author:
Brooks KEESHIN
1
;
Jeffrey R STRAWN
Author Information
1. Department of Pediatrics, University of Utah, Salt Lake City, UT, USA. brooks.keeshin@hsc.utah.edu
- Publication Type:Review
- Keywords:
Posttraumatic stress disorder;
Treatment;
Medication
- MeSH:
Adolescent*;
Adrenergic Antagonists;
Child;
Humans;
Psychotherapy;
Serotonin Uptake Inhibitors;
Standard of Care;
Stress Disorders, Post-Traumatic*
- From:Journal of the Korean Academy of Child and Adolescent Psychiatry
2017;28(1):14-19
- CountryRepublic of Korea
- Language:English
-
Abstract:
Children exposed to potentially traumatic events are at risk of developing posttraumatic stress disorder (PTSD). However, the subsequent developmental course of posttraumatic stress symptoms appears to vary considerably. In this regard, some PTSD symptoms resolve without significant interventions, while for many children and adolescents, they persist until the patient receives appropriate treatment specifically designed to address PTSD and other trauma related symptoms. Evidence-based psychotherapies represent the standard of care for children with PTSD and, while psychopharmacologic interventions are utilized for many youth with posttraumatic stress symptoms and PTSD, there is little data available to guide the use of these medications in this population. However, given the structural challenges involved in disseminating and delivering evidence-based psychotherapies in all settings, prescribing clinicians should be aware of the medications whose use in children with pediatric PTSD has been studied. Herein, we review the PTSD assessment modalities, as well as the use of pharmacologic interventions in PTSD, including antiadrenergic agents, selective serotonin reuptake inhibitors and other medications.
